Anti-IgE antibodies
    1.
    发明申请
    Anti-IgE antibodies 审中-公开
    抗IgE抗体

    公开(公告)号:US20080003218A1

    公开(公告)日:2008-01-03

    申请号:US11401765

    申请日:2006-04-11

    摘要: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

    摘要翻译: 本发明涉及通过以下步骤的组合来调节多肽与靶分子的亲和力的方法,包括:(1)鉴定易于异构化的天冬氨酰残基; (2)替代替代残基并筛选得到的突变体对靶分子的亲合力。 在优选的实施方案中,残基残基的方法是用噬菌体展示(AMPD)进行亲和力成熟。 在另一优选实施方案中,多肽是抗体,靶分子是抗原。 在另一个优选的实施方案中,抗体是抗IgE,靶分子是IgE。 在另一个实施方案中,本发明涉及对IgE具有改善的亲和力的抗IgE抗体。

    Method of Treatment Using Humanized Anti-CD11a Antibodies
    2.
    发明申请
    Method of Treatment Using Humanized Anti-CD11a Antibodies 审中-公开
    人源化抗CD11a抗体治疗方法

    公开(公告)号:US20070231328A1

    公开(公告)日:2007-10-04

    申请号:US11531667

    申请日:2006-09-13

    IPC分类号: A61K39/395

    摘要: Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of no more than about 1 nM in the mixed lymphocyte response assay.

    摘要翻译: 公开了人源化抗CD11a抗体及其各种用途。 和/或表达ICA-1的人类抗CD11a抗体可以特异性结合人CD11a I-结构域,具有不大于约1nM的IC 50(nM)值以防止Jurkat细胞粘附到正常的人表皮角化细胞上,和/或 在混合淋巴细胞反应测定中IC50(nM)值不超过约1nM。

    Method for treating multiple sclerosis
    6.
    发明申请
    Method for treating multiple sclerosis 审中-公开
    治疗多发性硬化症的方法

    公开(公告)号:US20050281817A1

    公开(公告)日:2005-12-22

    申请号:US11190410

    申请日:2005-07-26

    摘要: A method is provided for administering to a mammal suffering from, or at risk for, multiple sclerosis, an initial dosing of a therapeutically effective amount of an anti-LFA-1 antibody, followed by a subsequent intermittent dosing of a therapeutically effective amount of the anti-LFA-1 antibody wherein the antibody is administered to the mammal no more than once per week in the intermittent dosing.

    摘要翻译: 提供了一种给予患有或有多种硬化症风险的哺乳动物施用治疗有效量的抗LFA-1抗体的方法,随后间歇给予治疗有效量的 抗LFA-1抗体,其中在间歇给药中每周向哺乳动物施用抗体不超过一次。

    Temporal gamma-interferon administration for allergies
    7.
    发明授权
    Temporal gamma-interferon administration for allergies 失效
    临时γ-干扰素给药用于过敏

    公开(公告)号:US5112605A

    公开(公告)日:1992-05-12

    申请号:US325406

    申请日:1989-03-17

    申请人: Paula Jardieu

    发明人: Paula Jardieu

    IPC分类号: A61K38/21

    CPC分类号: A61K38/217

    摘要: Methods for the treatment of allergic reactions are provided, wherein a pharmaceutically effective dose of gamma interferon is administered to a patient within a predetermined temporal period prior to or following exposure to an allergen.

    摘要翻译: 提供了治疗过敏反应的方法,其中药物有效剂量的γ干扰素在暴露于变应原之前或之后在预定时间段内施用于患者。

    Methods for diagnosis of allergy
    9.
    发明授权
    Methods for diagnosis of allergy 失效
    过敏诊断方法

    公开(公告)号:US5714338A

    公开(公告)日:1998-02-03

    申请号:US393014

    申请日:1995-02-27

    摘要: Provided are methods for the diagnosis of allergic disease wherein IgE specific for an allergen of interest is detected in a patient serum sample by using the patient serum sample to sensitize in the presence or absence of an IgE antagonist a mast cell or basophil host genetically engineered to display surface expression of a Fc.epsilon.RI subunit that is capable of mediating the host cells release of a pharmacological mediator upon induction with patient serum and allergen, challenging the sensitized host cells with the allergen of interest, and determining the presence or absence of IgE specific to the allergen of interest in the patient serum sample by comparing the release of the pharmacological mediator produced by host cells sensitized with patient serum in the presence of the IgE antagonist to the release of the pharmacological mediator produced by host cells sensitized with patient serum in the absence of the IgE antagonist.

    摘要翻译: PCT No.PCT / US94 / 14282 Sec。 371日期:1995年2月27日 102(e)1995年2月27日PCT 1994年12月9日PCT PCT。 公开号WO95 / 16203 日期1995年6月15日提供了用于诊断过敏性疾病的方法,其中通过使用患者血清样品在存在或不存在IgE拮抗剂的情况下在患者血清样品中检测到感兴趣的变应原的IgE, 遗传工程改造的嗜碱性粒细胞宿主,以显示FcεRI亚基的表达表达,其能够在用患者血清和变应原诱导时介导宿主细胞释放药理学介质,并利用感兴趣的变应原对致敏宿主细胞进行挑战,并确定存在 或不存在对患者血清样品中感兴趣的变应原特异性的IgE,通过比较由存在IgE拮抗剂的患者血清致敏的宿主细胞产生的药理学介质与由致敏的宿主细胞产生的药理学介质的释放相关的释放 在没有IgE拮抗剂的情况下患有血清。